{"title":"阿布替尼治疗难治性毛疹红斑。","authors":"Filip Rob","doi":"10.4081/dr.2025.10105","DOIUrl":null,"url":null,"abstract":"<p><p>Pityriasis rubra pilaris is a rare idiopathic papulosquamous disorder that significantly impacts quality of life and is often refractory to conventional therapies. This study presents a case of successful treatment with an abrocitinib JAK1 inhibitor after several conventional and biologic therapies failed.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"17 3","pages":""},"PeriodicalIF":1.3000,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12421531/pdf/","citationCount":"0","resultStr":"{\"title\":\"Refractory pityriasis rubra pilaris treated with abrocitinib.\",\"authors\":\"Filip Rob\",\"doi\":\"10.4081/dr.2025.10105\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Pityriasis rubra pilaris is a rare idiopathic papulosquamous disorder that significantly impacts quality of life and is often refractory to conventional therapies. This study presents a case of successful treatment with an abrocitinib JAK1 inhibitor after several conventional and biologic therapies failed.</p>\",\"PeriodicalId\":11049,\"journal\":{\"name\":\"Dermatology Reports\",\"volume\":\"17 3\",\"pages\":\"\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2025-08-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12421531/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatology Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4081/dr.2025.10105\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/9 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4081/dr.2025.10105","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/9 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Refractory pityriasis rubra pilaris treated with abrocitinib.
Pityriasis rubra pilaris is a rare idiopathic papulosquamous disorder that significantly impacts quality of life and is often refractory to conventional therapies. This study presents a case of successful treatment with an abrocitinib JAK1 inhibitor after several conventional and biologic therapies failed.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
